Refsgaard Lasse, Holm Milo Marie Louise, Buhl Emma Skarsø, Jensen Jesper Møller, Maae Else, Berg Martin, Jensen Ingelise, Nielsen Mette Holck, Lorenzen Ebbe Laugaard, Thorsen Lise Bech Jellesmark, Korreman Stine Sofia, Offersen Birgitte Vrou
Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Oncology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Radiother Oncol. 2025 Mar;204:110705. doi: 10.1016/j.radonc.2024.110705. Epub 2024 Dec 25.
Radiotherapy improves outcomes for breast cancer. However, prior studies have correlated the risk of coronary artery disease (CAD) to the mean heart dose (MHD), mean dose to the left anterior descending artery (LAD_mean) and the left ventricle V5Gy (LV5). Other studies showed an increased risk of CAD for patients with pronounced coronary artery calcification (CAC) at the time of radiotherapy.
This cohort study included 3355 high-risk breast cancer patients treated in Western Denmark (2008-2016). We analysed CT scans, treatment plans, and dose distributions. CAC was measured using the Agatston score (AS). We examined the dose-response relationship between MHD, LV5 and LAD_mean and CAD, and the effect of CAC presence at radiotherapy. Secondary analysis assessed overall survival.
Of 3355 patients, 45 (1.2 %) developed CAD during follow-up. AS was a strong predictor of CAD risk with a hazard ratio of 9.51(CI95:5.16-17.53) for AS ≥ 100 versus AS < 100 and a 6.7 % difference in absolute cumulative CAD risk at ten years (7.7 % vs 1 %). For AS < 100 (97 % of patients) CAD risk increased with MHD, hazard ratio 1.25 (CI95:1.01-1.56) per Gy. ForAS ≥ 100, CAD risk was driven by CAC rather than radiation dose. CAC was associated with poorer overall survival. Median MHD for the whole cohort was 1.25 Gy (IQR:1.01-1.56).
AS from planning CT-scans predicted CAD risk and overall survival in breast cancer patients receiving radiotherapy. The MHD remained the strongest predictor in patients with low CAC. For patients with high CAC, the high baseline risk from CAC was a stronger risk factor than the dose-related risk.